The TT cell line (CRL-1803), derived from a human MTC harbours the RET/C634W mutation. In some studies, to assess the activity of sunitinib which is a potent inhibitor of VEGF receptor {(VEGFR)-1, VEGFR-2, VEGFR-3}, TT (RET/C634W) MTC cell line has been used.
You may want to refer to the articles attached below.
Article Identification of Soluble Candidate Biomarkers of Therapeuti...
Article Personalized Medicine in Medullary Thyroid Carcinoma: A Broa...